Pfizer Inc (NYS: PFE) Report Date Cash & cash equivalents 2020 1,784,000 2019 2018 1,305,000 1,139,000 Short-term investments Trade accounts receivable Inventories Current tax assets Other current assets Assets held for sale Total current assets Equity-method investments Long-term investments 10,437,000 8,525,000 17,694,000 7,930,000 8,724,000 8,025,000 8,047,000 8,284,000 7,508,000 3,264,000 3,344,000 3,374,000 3,438,000 2,600,000 2,461,000 167,000 21,000 9,725,000 35,067,000 32,803,000 49,926,000 16,856,000 17,133,000 3,406,000 3,014,000 2,767,000 Property, plant & equipment 13,900,000 13,967,000 13,385,000 Identifiable intangible assets 28,471,000 35,370,000 35,210,000 Goodwill 49,577,000 58,653,000 53,411,000 Noncurrent deferred tax assets & other noncurrent tax assets 2,383,000 2,099,000 1,924,000 Other noncurrent assets 4,569,000 4,450,000 Total assets 154,229,000 167,489,000 2,799,000 159,422,000 Liabilities Short-term borrowings, including current portion of long-term debt 2,703,000 16,195,000 8,831,000 Trade accounts payable 4,309,000 4,220,000 4,674,000 Dividends payable 2,162,000 2,104,000 2,047,000 Income taxes payable 1,049,000 980,000 1,265,000 Accrued compensation & related items 3,057,000 2,722,000 2,398,000 Other current liabilities 12,640,000 11,083,000 12,643,000 Total current liabilities Long-term debt Pension benefit obligations Postretirement benefit obligations Noncurrent deferred tax liabilities Other taxes payable Other noncurrent liabilities Total liabilities 25,920,000 37,304,000 31,858,000 37,133,000 35,955,000 32,909,000 4,766,000 5,638,000 5,272,000 645,000 1,124,000 1,338,000 4,063,000 5,578,000 3,700,000 11,560,000 12,126,000 14,737,000 6,669,000 6,317,000 5,850,000 90,756,000 104,042,000 95,664,000 Stockholders' Equity Preferred stock Common stock 470,000 Additional paid-in capital 88,674,000 Treasury stock 110,988,000 110,801,000 Retained earnings (accumulated deficit) 96,770,000 97,670,000 Accumulated other comprehensive income (loss) (11,688,000) Equity attributable to noncontrolling interests 235,000 Total equity (deficit) 63,473,000 (11,640,000) 305,000 63,447,000 17,000 468,000 87,428,000 19,000 467,000 86,253,000 101,610,000 89,554,000 (11,275,000) 350,000 63,758,000 Pfizer Inc (NYS: PFE) Report Date Revenues Cost of sales Gross Profit Selling, informational & administrative expenses Research & development expenses Amortization of intangible assets Restructuring charges & certain acquisition-related costs 2020 2019 2018 41,908,000 51,750,000 53,647,000 8,692,000 10,219,000 11,248,000 33,216,000 41,531,000 42,399,000 11,615,000 14,350,000 14,455,000 9,405,000 8,650,000 8,006,000 3,436,000 4,610,000 4,893,000 600,000 747,000 1,044,000 Gain (loss) on completion of Consumer Healthcare JV transaction 6,000 8,086,000 Interest income 73,000 Interest expense 1,449,000 Royalty-related income 770,000 226,000 1,574,000 648,000 333,000 1,316,000 other expenses 63,000 2,878,000 495,000 1,628,000 Income (loss) from continuing operations before provision for taxes on income Provision (benefit) for taxes on income 7,497,000 17,682,000 476,000 1,384,000 Income (loss) from continuing operations after provision for taxes on income 7,021,000 16,298,000 Income (loss) from discontinued operations - net of tax 2,631,000 Net income before allocation to noncontrolling interests 9,652,000 4,000 16,302,000 11,885,000 706,000 11,179,000 9,000 11,188,000 Less: net income attributable to noncontrolling interests Net income attributable to Pfizer Inc. (36,000) 9,616,000 (29,000) 16,273,000 (35,000) 11,153,000